Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity

Xin Yu(Baylor College of Medicine), Jin Wang(Baylor College of Medicine)

bioRxiv (Cold Spring Harbor Laboratory)

March 29, 2024

10.1101/2024.03.25.586133

Cited by 2

Related Papers

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

|Nature Communications|2020|204

Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation

|Nature Immunology|2020|202

Theoretical and Experimental Investigation of Thermodynamics and Kinetics of Thiol-Michael Addition Reactions: A Case Study of Reversible Fluorescent Probes for Glutathione Imaging in Single Cells

|Organic Letters|2015|77

H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2

|Cell Research|2018|77

Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug

|PLoS ONE|2015|38